{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T00:30:52Z","timestamp":1768005052790,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,1,1]],"date-time":"2010-01-01T00:00:00Z","timestamp":1262304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2010,1]]},"DOI":"10.1124\/jpet.109.158303","type":"journal-article","created":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T02:48:07Z","timestamp":1254278887000},"page":"4-16","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Reducing Abuse Liability of GABAA\/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at \u03b11 and \u03b12\/3 Subtypes"],"prefix":"10.1016","volume":"332","author":[{"given":"Nancy A.","family":"Ator","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Atack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Hargreaves","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Donald","family":"Burns","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard R.","family":"Dawson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.109.158303_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0014-2999(95)00633-8","article-title":"Central benzodiazepine receptor occupancy by zolpidem in the human brain as assessed by positron emission tomography","volume":"295","author":"Abadie","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.109.158303_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1517\/13543784.14.5.601","article-title":"The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics","volume":"14","author":"Atack","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1124\/jpet.109.158303_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/S1054-3589(08)57004-9","article-title":"Subtype-selective GABAA receptor modulation yields a novel pharmacological profile: the design and development of TPA023","author":"Atack","year":"2009","journal-title":"Adv Pharmacol"},{"key":"10.1124\/jpet.109.158303_bib4","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/jpet.105.089920","article-title":"TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an agonist selective for \u03b12- and \u03b13-containing GABAA receptors, is a non-sedating anxiolytic in rodents and primates","volume":"316","author":"Atack","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.109.158303_bib5","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0376-8716(00)00123-X","article-title":"Zaleplon and triazolam: drug discrimination, plasma levels, and self-administration in baboons","volume":"61","author":"Ator","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.109.158303_bib6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s00213-002-1076-4","article-title":"Relation between discriminative and reinforcing effects of midazolam, pentobarbital, chlordiazepoxide, zolpidem, and imidazenil in baboons","volume":"163","author":"Ator","year":"2002","journal-title":"Psychopharmacology"},{"key":"10.1124\/jpet.109.158303_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1017\/S1092852900009883","article-title":"Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders","volume":"10","author":"Ator","year":"2005","journal-title":"CNS Spectr"},{"issue":"Suppl 3","key":"10.1124\/jpet.109.158303_bib8","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1016\/S0376-8716(03)00099-1","article-title":"Principles of drug abuse liability assessment in laboratory animals","volume":"70","author":"Ator","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.109.158303_bib9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.drugalcdep.2004.09.007","article-title":"Self-injection of flunitrazepam alone and in the context of methadone maintenance in baboons","volume":"78","author":"Ator","year":"2005","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.109.158303_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0376-8716(00)00122-8","article-title":"Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons","volume":"61","author":"Ator","year":"2000","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.109.158303_bib11","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0006-8993(91)90131-E","article-title":"In vivo bidirectional modulatory effect of benzodiazepine receptor ligands on GABAergic transmission evaluated by positron emission tomography in non-human primates","volume":"557","author":"Brouillet","year":"1991","journal-title":"Brain Res"},{"key":"10.1124\/jpet.109.158303_bib12","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1021\/jm058034a","volume":"48","author":"Carling","year":"2005","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.109.158303_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0149-7634(85)90028-4","article-title":"Behavioural pharmacology of food, water and salt intake in relation to drug actions at benzodiazepine receptors","volume":"9","author":"Cooper","year":"1985","journal-title":"Neurosci Biobehav Rev"},{"key":"10.1124\/jpet.109.158303_bib14","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1017\/S1092852900009871","article-title":"Development of subtype selective GABAA modulators","volume":"10","author":"Dawson","year":"2005","journal-title":"CNS Spectr"},{"key":"10.1124\/jpet.109.158303_bib15","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1177\/0269881106072343","article-title":"Pharmacodynamic and pharmacokinetic effects of TPA023, a GABA(A) alpha(2,3) subtype-selective agonist, compared to lorazepam and placebo in healthy volunteers","volume":"21","author":"de Haas","year":"2007","journal-title":"J Psychopharmacol"},{"key":"10.1124\/jpet.109.158303_bib16","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/BF02244196","article-title":"Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons","volume":"103","author":"Griffiths","year":"1991","journal-title":"Psychopharmacology"},{"key":"10.1124\/jpet.109.158303_bib17","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0022-3565(25)11429-8","article-title":"Zolpidem behavioral pharmacology in baboons: self-injection, discrimination, tolerance and withdrawal","volume":"260","author":"Griffiths","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.109.158303_bib18","series-title":"Benzodiazepine Dependence","first-page":"58","article-title":"Benzodiazepine dependence syndromes and syndromes of withdrawal","author":"Higgitt","year":"1993"},{"key":"10.1124\/jpet.109.158303_bib19","series-title":"Benzodiazepine Dependence","first-page":"46","article-title":"Historical development of the concept of tranquilizer dependence","author":"Lader","year":"1993"},{"key":"10.1124\/jpet.109.158303_bib20","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0376-8716(84)90013-9","article-title":"Precipitated and spontaneous withdrawal in baboons after chronic dosing with lorazepam and CGS 9896","volume":"14","author":"Lamb","year":"1984","journal-title":"Drug Alcohol Depend"},{"key":"10.1124\/jpet.109.158303_bib21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00213-005-0060-1","article-title":"A proof-of-concept study using [11C]flumazenil PET to demonstrate that pagoclone is a partial agonist","volume":"180","author":"Lingford-Hughes","year":"2005","journal-title":"Psychopharmacology"},{"key":"10.1124\/jpet.109.158303_bib22","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1126\/science.6287579","article-title":"Precipitated withdrawal by a benzodiazepine receptor antagonist (Ro 15-1788) after 7 days of diazepam","volume":"217","author":"Lukas","year":"1982","journal-title":"Science"},{"key":"10.1124\/jpet.109.158303_bib23","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/0091-3057(82)90366-5","article-title":"A tethering system for intravenous and intragastric drug administration in the baboon","volume":"17","author":"Lukas","year":"1982","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1124\/jpet.109.158303_bib24","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S0028-3908(96)00072-X","article-title":"Benzodiazepine site pharmacokinetic\/pharmacodynamic quantification in man: direct measurement of drug occupancy and effects on the human brain in vivo","volume":"35","author":"Malizia","year":"1996","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.109.158303_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuropharm.2003.09.004","article-title":"Subtype-selective GABAergic drugs facilitate extinction of mouse operant behaviour","volume":"46","author":"McCabe","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1124\/jpet.109.158303_bib26","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/75761","article-title":"Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor \u03b11 subtype","volume":"3","author":"McKernan","year":"2000","journal-title":"Nat Neurosci"},{"key":"10.1124\/jpet.109.158303_bib27","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.108.138859","article-title":"NS11394 [3\u2032-[5-(1-hydroxy-1-methyl-ethyl)-benzoimidazol-1-yl]-biphenyl-2-carbonitrile], a unique subtype-selective GABAA receptor positive allosteric modulator: in vitro actions, pharmacokinetic properties and in vivo anxiolytic efficacy","volume":"327","author":"Mirza","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 2","key":"10.1124\/jpet.109.158303_bib28","first-page":"28","article-title":"Benzodiazepine use, abuse, and dependence","volume":"66","author":"O'Brien","year":"2005","journal-title":"J Clin Psychiatry"},{"key":"10.1124\/jpet.109.158303_bib29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0924-977X(91)90498-J","article-title":"Occupancy of the central benzodiazepine receptors during benzodiazepine treatment determined by PET","volume":"1","author":"Pauli","year":"1991","journal-title":"Eur J Neuropsychopharmacol"},{"key":"10.1124\/jpet.109.158303_bib30","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1073\/pnas.0405621102","article-title":"Different GABAA receptor subtypes mediate the anxiolytic, abuse-related, and motor effects of benzodiazepine-like drugs in primates","volume":"102","author":"Rowlett","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1124\/jpet.109.158303_bib31","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific \u03b3-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1124\/jpet.109.158303_bib32","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1097\/00008877-199210000-00009","article-title":"Behavioral pharmacology of abecarnil in baboons: self-injection, drug discrimination and physical dependence","volume":"3","author":"Sannerud","year":"1992","journal-title":"Behav Pharmacol"},{"key":"10.1124\/jpet.109.158303_bib33","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF00442808","article-title":"Detection of benzodiazepine receptor occupancy in the human brain by positron emission tomography","volume":"99","author":"Shinotoh","year":"1989","journal-title":"Psychopharmacology"},{"key":"10.1124\/jpet.109.158303_bib34","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2174\/1568026023393507","article-title":"Subunit composition, distribution and function of GABA(A) receptor subtypes","volume":"2","author":"Sieghart","year":"2002","journal-title":"Curr Top Med Chem"},{"key":"10.1124\/jpet.109.158303_bib35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0022-3565(24)37370-7","article-title":"Zolpidem physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons","volume":"285","author":"Weerts","year":"1998","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.109.158303_bib36","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1192\/bjp.173.5.361","article-title":"Benzodiazepines: time for reassessment","volume":"173","author":"Williams","year":"1998","journal-title":"Br J Psychiatry"},{"key":"10.1124\/jpet.109.158303_bib37","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/0091-3057(87)90500-4","article-title":"The benzodiazepine partial agonists, Ro 16-6028 and Ro 17-1812, increase palatable food consumption in nondeprived rats","volume":"28","author":"Yerbury","year":"1987","journal-title":"Pharmacol Biochem Behav"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524455894?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524455894?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.109.158303","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,20]],"date-time":"2025-02-20T02:03:02Z","timestamp":1740016982000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524455894"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,1]]}},"alternative-id":["S0022356524455894"],"URL":"https:\/\/doi.org\/10.1124\/jpet.109.158303","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2010,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reducing Abuse Liability of GABAA\/Benzodiazepine Ligands via Selective Partial Agonist Efficacy at \u03b11 and \u03b12\/3 Subtypes","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.109.158303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}